Haleon stock steady as director reinvests dividend into new shares
Published on 09/18/2026 at 20:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Haleon plc stock (ISIN GB00BMX86B70) drew attention after Senior Independent Non-Executive Director Alan Stewart acquired 242 ordinary shares through dividend reinvestment at a price of GBP 3.378619 per share on the London Stock Exchange on September 17, 2026, signalling continued insider alignment with shareholders.Investegate According to the same regulated disclosure, the transaction was executed on the London Stock Exchange, reinforcing London as the primary venue for Haleon shares.StockTitan
Insider dividend reinvestment and governance context
As Investegate reported on September 18, 2026, Alan Stewart acquired 242 Haleon ordinary shares via dividend reinvestment, with the price per share fixed at GBP 3.378619, implying a total reinvested amount of roughly GBP 817 when multiplying price and volume. The disclosure categorizes the transaction as a PDMR event, which underlines the governance framework that requires Haleon directors to report trades, giving investors visibility into insider activity.StockTitan
The PDMR filing summarized by StockTitan confirms that the transaction took place on the London Stock Exchange (XLON), reinforcing London as the liquid reference market for Haleon shares even though the company also maintains a listing in the FTSE 100 index. For investors, such dividend reinvestment by a senior independent director often supports a narrative of confidence in the company’s medium term prospects, especially when combined with Haleon’s visible footprint in the FTSE 100 constituents overview.Sharecast
Recent performance signals from FTSE 100 data
According to FTSE 100 constituent data compiled by Sharecast and accessed on September 17, 2026, Haleon is listed among the index members with a performance line that shows a 19.64% figure in the relevant performance column, alongside a 1.81% daily move and a 0.62% weighting component. While the table does not explicitly label each column, the 19.64% value is presented as a longer term performance indicator, which suggests that Haleon shares have gained 19.64% over the referenced period relative to the index baseline. In that same overview, Haleon is presented with a 1.81% change, implying that on the trading day captured in the table, Haleon’s move exceeded one percent, a useful quantitative checkpoint for shareholders looking at near term volatility.Sharecast
For context, the 19.64% performance figure from the FTSE 100 table offers a concrete comparison for investors: if Haleon’s share price had stood at an indexed 100 at the start of the period, a 19.64% move would correspond mathematically to a level of 119.64, highlighting that the stock has delivered nearly a one fifth increase across that timeframe as captured by the index data.Sharecast Combined with the director’s reinvestment of dividends at GBP 3.378619 per share on September 17, 2026, this paints a picture in which insider behaviour and index performance both point towards a constructive stance on Haleon’s equity profile.Investegate
Stock price level and investor takeaway
On the London Stock Exchange, Haleon shares are referenced at GBP 3.378619 in the director’s dividend reinvestment disclosure for the transaction executed on September 17, 2026, providing a precise price point that investors can compare to earlier dividend events and to the 19.64% performance value in the FTSE 100 table for Haleon.Investegate Without a separate intraday quote in the available sources, this GBP 3.378619 level from the regulated announcement is the most concrete recent reference in the current data set, and it stands as a benchmark price that fits into the observed 19.64% performance profile from the FTSE 100 constituent overview as of September 17, 2026.Sharecast
Haleon stock key data
- Company: Haleon plc
- ISIN: GB00BMX86B70
- Ticker: HLN
- Trading venue: London Stock Exchange
- Price (as of September 17, 2026): 3.378619 GBP
- Sector / Industry: Consumer healthcare
- Index membership: FTSE 100
